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Atazanavir (ATV) is a protease inhibitor used in the
treatment of HIV infection. It is useful in patients on
methadone replacement therapy as its once daily dosing
facilitates co-administration with methadone and, un-
like the non-nucleoside reverse transcriptase inhibitor,
efavirenz, it does not accelerate the metabolism of metha-
done via induction of cytochrome P450 enzymes [1]. ATV
is associated with unconjugated hyperbilirubinaemia in
6-40% of patients, overt jaundice in 7-8% and discontinu-
ation in up to 2% [2,3]. The pathophysiology of ATV-
hyperbilirubinaemia is analogous to Gilbert’s syndrome;
ATV competitively inhibits UDP-glucuronyltransferase
(UGT) enzymes leading to reduced glucuronidation of
bilirubin and increased levels of unconjugated bilirubin
[4,5]. Patients with the UGT1A1*28 genotype are particu-
larly, but not exclusively, vulnerable [6,7]. Our study aimed
to determine the clinical predictors of ATV-associated
hyperbilirubinaemia in our patient population.
Methods
We performed a single site, retrospective chart review of
all patients prescribed ATV at the Mater Misericordiae
University Hospital, Dublin between January 2004 and
October 2007. Data collected included baseline demo-
graphic/lifestyle factors (sex, age, ethnicity, acquisition risk
and methadone use), hepatitis B (HBV) and C (HCV)
serology, current and previous antiretroviral therapy, base-
line and week-12 routine bloods (urea and electrolytes, liver
function tests , HIV-RNA, CD4+ and CD8+ T-cell counts).
The last available bilirubin level for those who discontinued
ATV before week-12 was utilised in the analysis.
Data was entered into a Microsoft Access database
and analyses performed using SAS v9.13. Wilcoxon-
Mann–Whitney tests and Spearman’s correlation were* Correspondence: aoife.cotter@ucdconnect.ie
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reproduction in any medium, provided the orused to describe univariate associations between the fac-
tors of interest and the change in bilirubin over the first
12 weeks of ATV use. Factors considered in these
analyses were: gender; age; ethnicity [Caucasian, non-
Caucasian]; HIV exposure category [intravenous drug use
(IVDU), non-IVDU]; smoking status [current/ex-smoker,
non-smoker]; methadone use; AIDS status; CD4+ T-cell
count and HIV RNA <50 copies/ml at start of ATV; anti-
retroviral naïve/experienced at start of ATV; nucleoside
reverse transcriptase inhibitor (NRTI) included in regimen
[tenofovir (TDF), non-TDF] and laboratory parameters
(alkaline phosphatase (ALP), Υ-glutamyl transferase
(GGT), alanine aminotransferase (ALT), alkaline phos-
phatase (ALP), albumin (ALB), creatinine) at the time of
starting ATV, as well as the pre-ATV bilirubin level itself.
Factors that were associated with a change in bilirubin in
these analyses (P < 0.2) were then included in forward
stepwise multivariable linear regression analyses to identify
factors that were independently associated with the
change in bilirubin. As the change in bilirubin was skewed,
the change value was log-transformed prior to analysis;
estimates were back-transformed for presentation for ease
of interpretation. Due to the strong co-linearity of HCV
antibody positivity, methadone use and IVDU acquisition,
it was not possible to include all 3 variables in a single
model; therefore the primary model included HCV anti-
body status and sensitivity analyses were performed after
replacing this covariate in the model with IVDU acquisi-
tion or methadone use.Results
Ninety-three patients were prescribed ATV. Ten patients
were excluded from the analysis due to self-initiated
treatment interruption; these patients did not re-attend
clinic after the first prescription of ATV. Four subjects
discontinued ATV within 12 weeks; of these, one patient
had died, one patient discontinued early due to hepatitis
secondary to immune reconstitution and 2 patients
stopped ATV therapy due to jaundice. 83 patients were
included in the final analysis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics of 83 study participants, and median (IQR) change in bilirubin
concentrations over the first 12 weeks of ATV treatment
N (%) Median (IQR) change in bilirubin (μmol/L) P-value
Gender
Male 46 (55.4) 15 (4, 20) 0.23
Female 37 (44.6) 17 (4, 32)
Age (years)
Median (IQR) 33 (29, 40)
≤ 30 27 (32.5) 16 (3, 31)
31-40 38 (45.8) 15 (5, 21)
> 40 18 (21.7) 17.5 (1, 23) 0.75
Ethnicity
Caucasian 61 (73.5) 13 (4, 21)
Non-caucasian 22 (26.5) 21 (13, 32) 0.05
Acquisition risk
IVDU 51 (61.5) 13 (3, 20)
Non-IVDU 32 (38.5) 21 (12, 30) 0.01
AIDS
Yes 53 (63.9) 15 (4, 22)
No 30 (36.1) 17 (7, 21) 0.85
Methadone use
Yes 37 (44.6) 7 (1, 19) 0.001
No 46 (55.4) 20 (13, 26)
Hepatitis C antibody
Positive 46 (60.5) 10 (3, 20)
Negative 37 (39.5) 21 (13, 31) 0.01
Hepatitis C PCR
Positive 36 (43.4) 10 (3, 20)
Negative 47 (56.6) 20 (7, 29) 0.02
Hepatitis B sAG
Positive 4 (4.8) 17 (13, 27.5)
Negative 73 (90.0) 17 (4, 22) 0.55
Treatment status at baseline
Experienced 50 (60.2) 17 (4, 22) 0.21
Naïve 32 (38.6) 12 (2.5, 21)
HIV RNA <50 copies/ml at baseline
No 68 (81.9) 14 (3.5, 21.5)
Yes 15 (18.1) 18 (13, 22) 0.31
NRTI
TDF 42 (42.2) 11 (2, 20)
Non-TDF 41 (50.6) 18 (19, 24) 0.02
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in Table 1. Approximately half the study group were
male (55.4%), the median (IQR) age was 33 (29, 40)
years, three-quarters (73.5%) were Caucasian and one-
quarter were (21 (25.3%) of African ethnicity. The me-
dian (IQR) body mass index was 23 (19.5, 26.0) kg/m2.HIV acquisition risk was via IVDU in 61.5%, heterosex-
ual sex in 34.9%, and homosexual sex in 3.6%. Due to
the high proportion of IVDU, methadone use (44.6%)
and hepatitis C virus co-infection (60.5%) were common.
The majority (79 (95.2%)) were co-administered 300 mg
ATV with 100 mg ritonavir, with the remainder being
Table 2 Baseline and week-12 bilirubin grade
Week 12
Baseline N (%) 0 1 2 3 4
0 78 (94.0) 27 20 21 9 1
1 4 (4.8) 2 1 1 0 0
2 1 (1.2) 0 1 0 0 0
Total 83 (100.0) 29 (35.0) 22 (26.5) 22 (26.5) 9 (10.8) 1 (1.2)
Bilirubin grade defined as per AIDS Clinical Trials Guidelines; Grade 0, normal;
Grade 1, 1–1.5 × upper limit normal (ULN) (21–30 μmol/L); Grade 2, 1.5-2.5 ×
ULN (31–45 μmol/L); Grade 3, 2.5-5.0 × ULN (46–100 μmol/L); Grade 4, >
5 × ULN (>100 μmol/L).
Cotter et al. AIDS Research and Therapy 2013, 10:13 Page 3 of 5
http://www.aidsrestherapy.com/content/10/1/13administered 400 mg ATV. Just under half of patients
(42.2%) started TDF as part of their regimen, with 35 of
the remaining 41 patients starting a regimen that
contained abacavir (ABC). Median (IQR) CD4 + T-cell
count, ALP, ALT and GGT were 165 (82, 264) cells/mm3,
79 (64, 107) IU, 35 (18, 50) IU and 52 (25, 122) IU at base-
line, respectively. At baseline, 15 (18.1%) subjects had
undetectable HIV RNA (<50 copies/ml) compared to 45
(54.9%) at week 12, while 46 (80.5%) had HIV RNA
< 400 copies/ml at week 12.
Bilirubin levels increased from 11 (9, 14) μmol/L at
baseline to 27 (17, 35) μmol/L at week-12; the median
(IQR) change was 16 (4, 22) μmol/L. Five patients had
elevated bilirubin at baseline (4 with grade 1 elevation, 1
with a grade 2 elevation); by week 12, all five continued
to have elevated bilirubin (Table 2). In contrast, of the
78 patients with a normal bilirubin at baseline, 49 (63%)
had an elevated level at week 12 (Table 2).Table 3 Results from multivariate linear regression final mod
in bilirubin over the first 12 weeks of ATV treatment
Relative change i
bilirubin
Main model – with HCV
seropositivity
Baseline ALP (/5 IU increase) 0.99
TDF use at baseline 0.86
HCV seropositivity 0.80
Baseline bilirubin 0.98
Sensitivity analysis 1 – with
methadone use
ALP at baseline (/5 IU increase) 0.99
TDF use at baseline 0.83
Methadone use 0.77
Baseline bilirubin 0.98
Sensitivity analysis 2 – with IVDU
ALP at baseline (/5 IU increase) 0.99
TDF use at baseline 0.83
IVDU 0.85
Baseline bilirubin 0.98Univariate analyses (Table 1) suggested that Caucasian
ethnicity, TDF use, HCV antibody positivity and metha-
done use were significantly associated with change in
bilirubin. With respect to the continuous variables that
were considered, higher levels of ALT (r = −0.23, P = 0.04),
GGT (r = −0.30, P = 0.005) and ALP (r = −0.43, P < 0.0001)
at the time of starting ATV were all significantly associ-
ated with a smaller increase in bilirubin. Neither BMI nor
baseline CD4 + T-cell count significantly correlated with
change in bilirubin concentration (r = −0.08, P = 0.62;
r = 0.06, P = 0.56 respectively). Changes in bilirubin were
generally but not significantly lower in those with higher
pre-ATV levels (r = −0.10, P = 0.37).
Of the parameters considered, the following variables
(P < 0.05) were therefore considered for inclusion in a
forward stepwise linear regression model: baseline ALP,
ALT, GGT, TDF use, Caucasian ethnicity and HCV
antibody status. Of these, only baseline ALP and HCV
antibody positivity were independently associated with a
smaller change in bilirubin (P = 0.04 and 0.03, respect-
ively, Table 3) after adjusting for baseline bilirubin,
higher levels of which were also associated with smaller
changes after initiation of ATV. In particular, the mean
increase in bilirubin was reduced by 1% per 5 IU increment
in ALP, by 20% in those who were HCV seropositive, and
by 2% per mmol/L increment in baseline bilirubin.
When sensitivity analyses were performed in which
HCV antibody positivity was replaced by methadone use
or IVDU status, similar results were obtained. In par-
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use were independently associated with a smaller change
in bilirubin (P-values of 0.01, 0.04 and 0.01, respectively),
after adjusting for baseline bilirubin. When the analysis
was performed with IVDU status replacing HCV anti-
body positivity, baseline ALP, and TDF use were inde-
pendently associated with a smaller change in bilirubin
concentration (P-values of 0.02 and 0.05 respectively).
Finally, the exclusion of 2 subjects who discontinued
ATV within 4 weeks due to jaundice did not alter our
findings appreciably.
Discussion
Our data demonstrate that higher baseline ALP and
HCV seropositivity predict smaller changes in bilirubin
after initiation of ATV. Sensitivity analyses determined
that methadone use/intravenous drug use and TDF–use
were independently associated with a smaller change in
bilirubin.
Patients with chronic hepatitis B or C co-infection are
at greater risk of drug-induced liver injury and liver en-
zyme elevations than those without co-infection [8,9],
therefore it is plausible that they might be at greater risk
of ATV-induced hyperbilirubinaemia. We have come to
the opposite conclusion; those with HCV infection gen-
erally experience smaller increases in bilirubin concen-
trations after initiating ATV. This is the first paper that
focuses on the clinical predictors of change in bilirubin
level, with the majority of the literature focusing on gen-
etic predictors. Rotger et al. assessed the utility of geno-
typing and hyperbilirubinaemia and found that chronic
hepatitis C and hepatitis B infection were associated with
higher bilirubin levels [6]. The authors suggested that pre-
treatment screening for UGT1A1*28 genotype would
reduce the prevalence of jaundice from 22% to 5%. How-
ever, testing is expensive and impractical in everyday prac-
tice and may result in avoidance of use of ATV in patients
who would potentially benefit from its use.
On sensitivity analysis involving the substitution
of intravenous drug use or methadone use for HCV
seropositivity, we determined that intravenous drug use
or methadone use were associated with smaller change
in bilirubin at week 12. There are 2 plausible explana-
tions: intravenous drug use history and/ or methadone
use are surrogate markers for hepatitis C seropositivity
in this cohort or methadone co-administration affects
plasma concentrations of ATV. The latter is supported
by a pharmacokinetic study of the co-administration of
methadone and ATV that demonstrated significantly
lower maximum concentrations (Cmax) of plasma ATV
in those on concomitant methadone [10]. However, in this
previous study, despite lower ATV levels, there was no dif-
ference in the therapeutic efficacy of ATV. Although we
did not measure plasma ATV concentrations in this study,the previous finding of maintenance of virological efficacy
is reflected in the high levels of HIV viral suppression in
our cohort. Finally, we found that concomitant use of
TDF is independently associated with a smaller change in
bilirubin is consistent with previous data that concomitant
TDF use has been shown to lower ATV levels [11].
While our study benefited from the use of longitudinal
data and a representative sample of patients (drug-users
versus non-drug users, Caucasian and non-Caucasian
ethnicity), it was limited by its relatively small sample
size and its retrospective nature. There was no data
regarding compliance although the fact that majority of
subjects had an undetectable viral load would suggest
adequate adherence. In conclusion, we determined that
HCV antibody positivity and higher baseline bilirubin
were associated with a smaller increase in bilirubin after
initiation of ATV. Ultimately, this data is clinically useful
and may reassure prescribing physicians regarding the
merit of ATV use for intravenous drug users who are
co-infected with HCV, particularly in resource limited
settings where regular monitoring of liver function tests
may not be feasible. Further research is required to iden-
tify clinical predictors that are readily utilisable in every-
day practice.
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